Figure 1.

Recurrence-free survival is better in patients receiving an intensive maintenance schedule than in those who received an induction course alone or less intensive maintenance. BCG, bacillus Calmette-Guérin; SWOG, Southwest Oncology Group. This figure was published in Journal of Urology, Volume 163, Lamm DL et al, “Maintenance bacillus Calmette- Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study,” pages 1124–1129, Copyright American Urological Association, Inc., 2000.